

# **Heparin Sales Market By Type (Low Molecular Weight Heparin, Ultra-low Molecular Weight Heparin, and Unfractionated Heparin), Application (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease and Others), End-Use (Outpatient and Inpatient) and Geography – Global Forecast up to 2026**

<https://marketpublishers.com/r/HE42C6EB0310EN.html>

Date: July 2021

Pages: 131

Price: US\$ 4,000.00 (Single User License)

ID: HE42C6EB0310EN

## **Abstracts**

Heparin is a sulfur-containing polysaccharide that functions as a blood thinner. Heparin is used to treat heart conditions that include unstable angina and prevent the development of blood clots inside blood vessels. Heparin is also used in dialysis treatment while blood transfusion and post-surgeries. Heparin is generally injected directly into the muscle or the veins to break down the clots and maintain an easy flow of the blood. The Heparin Sales Market is expected to grow at the rate of 5.2% CAGR by 2026. One of the key factors to compel the heparin sales market growth is the rising old population affected mainly by venous thrombosis. Venous thromboembolism (VTE) is the most common disorder in the old population; it can occur at any age. The prevalence rate of numerous diseases such as heart failure can result in thrombosis and most commonly occur in the geriatric population compared to the young age population. However, the adverse impacts of heparin are the key impeding factor of the market.

Heparin Sales Market on the basis of Type

Low Molecular Weight Heparin

Ultra-low Molecular Weight Heparin

## Unfractionated Heparin

### Heparin Sales Market on the basis of Application

Venous Thromboembolism

Atrial Fibrillation

Renal Impairment

Coronary Artery Disease

Others

### Heparin Sales Market on the basis of End Use

Outpatient

Inpatient

### Heparin Sales Market on the basis of Geography

North America

Europe

Asia Pacific

Rest of the World

The low molecular weight heparin segment has the most significant share in the market. This is due to the high anticipated anticoagulant effect of the product. Moreover, the significant share is due to the high adoption of the low molecular weight heparin in the developed countries, the high pricing of these product offerings, and the more safety

profiles of this type of product compared to other products.

Further, the venous thromboembolism segment is expected to register the highest growth rate over the forecasted years. The highest growth is attributed to the increasing awareness about thrombosis and the increasing cases of venous thromboembolism. The venous thromboembolism is further categorized into pulmonary embolism (PE) and deep vein thrombosis (DVT).

As per the end-user, the market is bifurcated into outpatient and inpatient. The outpatient segment is projected to have a substantial growth rate in the market. The preference for a subcutaneous route of administration among the patients is increasing, which is a key factor for the segment growth. Moreover, the cost of outpatient treatment is low when compared to inpatient hospital costs.

North America has held a maximum share in the heparin sales market compared to other regions. The maximum share is accredited to the growing injuries in sports and rising cardiovascular disorders. In addition, the huge healthcare expenditure levels, rising patient awareness, and experienced healthcare infrastructure in this region are the factors attributed to the region's maximum share.

Few factors that are majorly accelerating the global heparin market growth are the rising number of accidents and medical surgeries globally, which is increasing demand for heparin. The growing disorders such as cardiovascular disorders will spur the demand for heparin. An increase in the investments to develop healthcare infrastructure and the increasing awareness among patients are also expected to boost the market demand.

The major market companies of the heparin sales market include Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Aspen Pharmacare Holdings Ltd., Baxter International Inc., Laboratorios Farmaceuticos Rovi SA, Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Mylan NV, Pfizer Inc., and Sanofi S.A.

Henceforth, the increasing prevalence of the diseases such as coronary heart disease and myocardial infections and the increasing number of accidents and injuries lead to blood clots during surgeries. Heparin is playing a prominent role in preventing blood clots from forming.

This report of the heparin sales market consists of qualitative factors such as factors propelling and restraining and generating opportunities.

This study depicts the competitive analysis of significant players in the heparin sales market and their strategic developments in the product.

This research provides the analysis based on qualitative and quantitative of the market segmented.

Additionally, this report consists of actual market shares and forecasts for all the segments which are mentioned in the report.

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. INDUSTRY OUTLOOK**

2.1. Industry Overview

2.2. Industry Trends

### **3. MARKET SNAPSHOT**

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

### **4. MARKET CHARACTERISTICS**

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

### **5. TYPE: MARKET SIZE & ANALYSIS**

5.1. Overview

5.2. Low Molecular Weight Heparin

5.3. Ultra-low Molecular Weight Heparin

5.4. Unfractionated Heparin

### **6. APPLICATION: MARKET SIZE & ANALYSIS**

6.1. Overview

6.2. Venous Thromboembolism

6.3. Atrial Fibrillation

6.4. Renal Impairment

6.5. Coronary Artery Disease

6.6. Others

## **7. END-USE: MARKET SIZE & ANALYSIS**

7.1. Overview

7.2. Outpatient

7.3. Inpatient

## **8. GEOGRAPHY: MARKET SIZE & ANALYSIS**

8.1. Overview

8.2. North America

8.3. Europe

8.4. Asia Pacific

8.5. Rest of the World

## **9. COMPETITIVE LANDSCAPE**

9.1. Competitor Comparison Analysis

9.2. Market Developments

9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

9.2.2. Product Launches and execution

## **10. VENDOR PROFILES**

10.1. Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd

10.1.1. Overview

10.1.2. Financial Overview

10.1.3. Product Offerings

10.1.4. Developments

10.1.5. Business Strategy

10.2. Aspen Pharmacare Holdings Ltd.

10.2.1. Overview

10.2.2. Financial Overview

10.2.3. Product Offerings

10.2.4. Developments

10.2.5. Business Strategy

10.3. Baxter International Inc.

- 10.3.1. Overview
- 10.3.2. Financial Overview
- 10.3.3. Product Offerings
- 10.3.4. Developments
- 10.3.5. Business Strategy
- 10.4. Laboratorios Farmaceuticos Rovi SA
  - 10.4.1. Overview
  - 10.4.2. Financial Overview
  - 10.4.3. Product Offerings
  - 10.4.4. Developments
  - 10.4.5. Business Strategy
- 10.5. Eisai Co. Ltd.
  - 10.5.1. Overview
  - 10.5.2. Financial Overview
  - 10.5.3. Product Offerings
  - 10.5.4. Developments
  - 10.5.5. Business Strategy
- 10.6. Fresenius SE & Co. KGaA
  - 10.6.1. Overview
  - 10.6.2. Financial Overview
  - 10.6.3. Product Offerings
  - 10.6.4. Developments
  - 10.6.5. Business Strategy
- 10.7. Hikma Pharmaceuticals Plc
  - 10.7.1. Overview
  - 10.7.2. Financial Overview
  - 10.7.3. Product Offerings
  - 10.7.4. Developments
  - 10.7.5. Business Strategy
- 10.8. Mylan NV
  - 10.8.1. Overview
  - 10.8.2. Financial Overview
  - 10.8.3. Product Offerings
  - 10.8.4. Developments
  - 10.8.5. Business Strategy
- 10.9. Pfizer Inc.
  - 10.9.1. Overview
  - 10.9.2. Financial Overview
  - 10.9.3. Product Offerings

- 10.9.4. Developments
- 10.9.5. Business Strategy
- 10.10. Sanofi S.A.
  - 10.10.1. Overview
  - 10.10.2. Financial Overview
  - 10.10.3. Product Offerings
  - 10.10.4. Developments
  - 10.10.5. Business Strategy

## **11. ANALYST OPINION**

## **12. ANNEXURE**

- 12.1. Report Scope
- 12.2. Market Definitions
- 12.3. Research Methodology
  - 12.3.1. Data Collation and In-house Estimation
  - 12.3.2. Market Triangulation
  - 12.3.3. Forecasting
- 12.4. Report Assumptions
- 12.5. Declarations
- 12.6. Stakeholders
- 12.7. Abbreviations



## List Of Tables

### LIST OF TABLES

TABLE 1. GLOBAL HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 2. GLOBAL HEPARIN SALES MARKET VALUE FOR LOW MOLECULAR WEIGHT HEPARIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 3. GLOBAL HEPARIN SALES MARKET VALUE FOR ULTRA-LOW MOLECULAR WEIGHT HEPARIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 4. GLOBAL HEPARIN SALES MARKET VALUE FOR UNFRACTIONATED HEPARIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 5. GLOBAL HEPARIN SALES MARKET VALUE, BY APPLICATION, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 6. GLOBAL HEPARIN SALES MARKET VALUE FOR VENOUS THROMBOEMBOLISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 7. GLOBAL HEPARIN SALES MARKET VALUE FOR ATRIAL FIBRILLATION, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 8. GLOBAL HEPARIN SALES MARKET VALUE FOR RENAL IMPAIRMENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 9. GLOBAL HEPARIN SALES MARKET VALUE FOR CORONARY ARTERY DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 10. GLOBAL HEPARIN SALES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 11. GLOBAL HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 12. GLOBAL HEPARIN SALES MARKET VALUE FOR OUTPATIENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 13. GLOBAL HEPARIN SALES MARKET VALUE FOR INPATIENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 14. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 15. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 16. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 17. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 18. U.S HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD

BILLION)

TABLE 19. U.S HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026  
(USD BILLION)

TABLE 20. U.S HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD  
BILLION)

TABLE 21. CANADA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

TABLE 22. CANADA HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

TABLE 23. CANADA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026  
(USD BILLION)

TABLE 24. EUROPE HEPARIN SALES MARKET VALUE, BY COUNTRY, 2020-2026  
(USD BILLION)

TABLE 25. EUROPE HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

TABLE 26. EUROPE HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

TABLE 27. EUROPE HEPARIN SALES MARKET VALUE, END-USE, 2020-2026 (USD  
BILLION)

TABLE 28. GERMANY HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026  
(USD BILLION)

TABLE 29. GERMANY HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

TABLE 30. GERMANY HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026  
(USD BILLION)

TABLE 31. U.K HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

TABLE 32. U.K HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026  
(USD BILLION)

TABLE 33. U.K HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD  
BILLION)

TABLE 34. FRANCE HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

TABLE 35. FRANCE HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

TABLE 36. FRANCE HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026  
(USD BILLION)

TABLE 37. ITALY HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

TABLE 38. ITALY HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 39. ITALY HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 40. SPAIN HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 41. SPAIN HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 42. SPAIN HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 43. ROE HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 44. ROE HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 45. ROE HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 46. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 47. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 48. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 49. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 50. CHINA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 51. CHINA HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 52. CHINA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 53. INDIA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 54. INDIA HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 55. INDIA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

TABLE 56. JAPAN HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

TABLE 57. JAPAN HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026

(USD BILLION)

TABLE 58. JAPAN HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026

(USD BILLION)

TABLE 59. REST OF APAC HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026

(USD BILLION)

TABLE 60. REST OF APAC HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

TABLE 61. REST OF APAC HEPARIN SALES MARKET VALUE, BY END-USE,  
2020-2026 (USD BILLION)

TABLE 62. REST OF WORLD HEPARIN SALES MARKET VALUE, BY TYPE,  
2020-2026 (USD BILLION)

TABLE 63. REST OF WORLD HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

TABLE 64. REST OF WORLD HEPARIN SALES MARKET VALUE, BY END-USE,  
2020-2026 (USD BILLION)

TABLE 65. NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO. LTD:  
FINANCIALS

TABLE 66. NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO. LTD:  
PRODUCTS & SERVICES

TABLE 67. NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO. LTD:  
RECENT DEVELOPMENT

TABLE 68. ASPEN PHARMACARE HOLDINGS LTD: FINANCIALS

TABLE 69. ASPEN PHARMACARE HOLDINGS LTD: PRODUCTS & SERVICES

TABLE 70. ASPEN PHARMACARE HOLDINGS LTD: RECENT DEVELOPMENTS

TABLE 71. BAXTER INTERNATIONAL INC: FINANCIALS

TABLE 72. BAXTER INTERNATIONAL INC: PRODUCTS & SERVICES

TABLE 73. BAXTER INTERNATIONAL INC: RECENT DEVELOPMENTS

TABLE 74. LABORATORIOS FARMACEUTICOS ROVI SA: FINANCIALS

TABLE 75. LABORATORIOS FARMACEUTICOS ROVI SA: PRODUCTS & SERVICES

TABLE 76. LABORATORIOS FARMACEUTICOS ROVI SA: RECENT  
DEVELOPMENTS

TABLE 77. EISAI CO. LTD: FINANCIALS

TABLE 78. EISAI CO. LTD: PRODUCTS & SERVICES

TABLE 79. EISAI CO. LTD: RECENT DEVELOPMENTS

TABLE 80. FRESENIUS SE & CO. KGAA: FINANCIALS

TABLE 81. FRESENIUS SE & CO. KGAA: PRODUCTS & SERVICES

TABLE 82. FRESENIUS SE & CO. KGAA: RECENT DEVELOPMENTS

TABLE 83. HIKMA PHARMACEUTICALS PLC: FINANCIALS

TABLE 84. HIKMA PHARMACEUTICALS PLC: PRODUCTS & SERVICES

TABLE 85. HIKMA PHARMACEUTICALS PLC: RECENT DEVELOPMENTS

TABLE 86. MYLAN NV: FINANCIALS

TABLE 87. MYLAN NV: PRODUCTS & SERVICES

TABLE 88. MYLAN NV: RECENT DEVELOPMENTS

TABLE 89. PFIZER INC: FINANCIALS

TABLE 90. PFIZER INC: PRODUCTS & SERVICES

TABLE 91. PFIZER INC: RECENT DEVELOPMENTS

TABLE 92. SANOFI S.A: FINANCIALS

TABLE 93. SANOFI S.A: PRODUCTS & SERVICES

TABLE 94. SANOFI S.A: RECENT DEVELOPMENTS

## List Of Figures

### LIST OF FIGURES

CHART. 1. GLOBAL HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 2. GLOBAL HEPARIN SALES MARKET VALUE FOR LOW MOLECULAR WEIGHT HEPARIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 3. GLOBAL HEPARIN SALES MARKET VALUE FOR ULTRA-LOW MOLECULAR WEIGHT HEPARIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 4. GLOBAL HEPARIN SALES MARKET VALUE FOR UNFRACTIONATED HEPARIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 5. GLOBAL HEPARIN SALES MARKET VALUE, BY APPLICATION, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 6. GLOBAL HEPARIN SALES MARKET VALUE FOR VENOUS THROMBOEMBOLISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 7. GLOBAL HEPARIN SALES MARKET VALUE FOR ATRIAL FIBRILLATION, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 8. GLOBAL HEPARIN SALES MARKET VALUE FOR RENAL IMPAIRMENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 9. GLOBAL HEPARIN SALES MARKET VALUE FOR CORONARY ARTERY DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 10. GLOBAL HEPARIN SALES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 11. GLOBAL HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 12. GLOBAL HEPARIN SALES MARKET VALUE FOR OUTPATIENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 13. GLOBAL HEPARIN SALES MARKET VALUE FOR INPATIENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)

CHART. 14. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

CHART. 15. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 16. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

CHART. 17. NORTH AMERICA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 18. U.S HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD

BILLION)

CHART. 19. U.S HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026  
(USD BILLION)

CHART. 20. U.S HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD  
BILLION)

CHART. 21. CANADA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

CHART. 22. CANADA HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

CHART. 23. CANADA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026  
(USD BILLION)

CHART. 24. EUROPE HEPARIN SALES MARKET VALUE, BY COUNTRY, 2020-2026  
(USD BILLION)

CHART. 25. EUROPE HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

CHART. 26. EUROPE HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

CHART. 27. EUROPE HEPARIN SALES MARKET VALUE, END-USE, 2020-2026  
(USD BILLION)

CHART. 28. GERMANY HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026  
(USD BILLION)

CHART. 29. GERMANY HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

CHART. 30. GERMANY HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026  
(USD BILLION)

CHART. 31. U.K HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

CHART. 32. U.K HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026  
(USD BILLION)

CHART. 33. U.K HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD  
BILLION)

CHART. 34. FRANCE HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)

CHART. 35. FRANCE HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

CHART. 36. FRANCE HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026  
(USD BILLION)

CHART. 37. ITALY HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD  
BILLION)



CHART. 38. ITALY HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

CHART. 39. ITALY HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 40. SPAIN HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 41. SPAIN HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

CHART. 42. SPAIN HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 43. ROE HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 44. ROE HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

CHART. 45. ROE HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 46. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

CHART. 47. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 48. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

CHART. 49. ASIA PACIFIC HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 50. CHINA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 51. CHINA HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

CHART. 52. CHINA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 53. INDIA HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 54. INDIA HEPARIN SALES MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

CHART. 55. INDIA HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026 (USD BILLION)

CHART. 56. JAPAN HEPARIN SALES MARKET VALUE, BY TYPE, 2020-2026 (USD BILLION)

CHART. 57. JAPAN HEPARIN SALES MARKET VALUE, BY APPLICATION,



2020-2026 (USD BILLION)

CHART. 58. JAPAN HEPARIN SALES MARKET VALUE, BY END-USE, 2020-2026  
(USD BILLION)

CHART. 59. REST OF APAC HEPARIN SALES MARKET VALUE, BY TYPE,  
2020-2026 (USD BILLION)

CHART. 60. REST OF APAC HEPARIN SALES MARKET VALUE, BY APPLICATION,  
2020-2026 (USD BILLION)

CHART. 61. REST OF APAC HEPARIN SALES MARKET VALUE, BY END-USE,  
2020-2026 (USD BILLION)

CHART. 62. REST OF WORLD HEPARIN SALES MARKET VALUE, BY TYPE,  
2020-2026 (USD BILLION)

CHART. 63. REST OF WORLD HEPARIN SALES MARKET VALUE, BY  
APPLICATION, 2020-2026 (USD BILLION)

CHART. 64. REST OF WORLD HEPARIN SALES MARKET VALUE, BY END-USE,  
2020-2026 (USD BILLION)

## I would like to order

Product name: Heparin Sales Market By Type (Low Molecular Weight Heparin, Ultra-low Molecular Weight Heparin, and Unfractionated Heparin), Application (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease and Others), End-Use (Outpatient and Inpatient) and Geography – Global Forecast up to 2026

Product link: <https://marketpublishers.com/r/HE42C6EB0310EN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HE42C6EB0310EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970